The PathHunter® Tocilizumab Bioassay kit provides an easy-to-use cell based assay to measure drug potency and detect neutralizing antibodies. This bioassay assesses ligand (e.g. IL-6) induced dimerization of IL-6ST and IL-6R. receptors. This product uses EFC technology. The cell line included overexpresses IL-6ST target protein fused to PK alongside IL-6R target protein fused to EA. Upon ligand-induced dimerization of IL-6ST and IL-6R, detectable EFC signal is produced. This assay has been optimized and qualified with Actemra (not supplied in the bioassay kit). Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group. Bioassay kits are a convenient, ready-to-use format which contains all materials needed to run the assay, including single-use vials of cryopreserved cells, cell plating media, control agonist, detection reagent, and assay plates.
IL-6 Receptor Family
interleukin 6 receptorIL6Qgp80CD126HIES5IL-6RIL6RAIL6RQIL-1RaIL-6RAIL6QTLIL-6R-1
Potency, Commercial Release & Stability
Short term (24 h): Store in vapor phase of liquid nitrogen.
These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.
Actemra® is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group